New Dawn Health
Printed Nov 22, 2026
newdawn.health/blog/cancer-screening-guidelines-us-taiwan-japan-korea
Health Screening ·

Cancer Screening Guidelines in the US, Taiwan, Japan and Korea, Side by Side

The US, Taiwan, Japan and Korea all screen for colorectal, breast, cervical and lung cancer, at different ages and with different tests. Japan and Korea also screen the stomach every 2 years, from 50 and 40. Korea scans the liver every 6 months in adults 40 and over with hepatitis B or C, and Taiwan examines betel-nut chewers' and smokers' mouths every 2 years. None of the three Asian programmes screens for prostate or thyroid cancer.

All four countries screen healthy adults for colorectal, breast, cervical and lung cancer, at different ages and intervals. They part ways on three organs. Japan and Korea look at the stomach every 2 years. Korea scans the liver every 6 months in adults 40 and over who carry hepatitis B or C or have cirrhosis. Taiwan examines the mouths of betel-nut chewers and smokers every 2 years. None of the three Asian national programmes screens for prostate or thyroid cancer.

This page sets the four programmes side by side, cited to each government's own documents as of October 2026. It then explains why the lists differ and which Asian check-up extras have evidence behind them for a US reader.

What does each country's national programme screen for?

Each row gives age, interval and test. Unless a bracket names another source, Japan's rows come from the MHLW guideline (revised 7 October 2026), Korea's from the National Cancer Screening Program (NCSP) paper of 2025, and Taiwan's from the HPA. "Not in the programme" means the cancer is absent from that country's official list.

Colorectal cancer

CountryProgramme
United States45–75: FIT every year, stool DNA-FIT every 1–3 years, CT colonography every 5 years, or colonoscopy every 10 years (USPSTF 2021). The ACS 2026 update also starts at 45
Taiwan45–74: FIT every 2 years. 40–44 if a parent, child or sibling had colorectal cancer
Japan40 and over, priority 40–69: FIT every year
Korea50 and over: FIT every year, colonoscopy if positive

Breast cancer

CountryProgramme
United StatesWomen 40–74: mammogram every 2 years (USPSTF 2024)
TaiwanWomen 40–74: mammogram every 2 years
JapanWomen 40 and over, priority 40–69: mammogram every 2 years
KoreaWomen 40 and over: mammogram every 2 years

Cervical cancer

CountryProgramme
United States21–29: Pap every 3 years. 30–65: Pap every 3 years, HPV test every 5 years, or both every 5 years (USPSTF 2018, update in progress). The ACS prefers an HPV test every 5 years from 25 to 65 (revised Dec 2025)
Taiwan25–29: Pap every 3 years. 30 and over: Pap subsidised yearly, at least every 3 years advised. An HPV test is added at 35, 45 and 65 (MOHW Dec 2024)
Japan20 and over, priority 20–69: Pap every 2 years. 30 and over, priority 30–60: HPV test alone every 5 years, where the city offers it
KoreaWomen 20 and over: Pap every 2 years

Lung cancer

CountryProgramme
United States50–80 with 20 or more pack-years, still smoking or quit within 15 years: low-dose CT every year (USPSTF 2021)
TaiwanLow-dose CT every 2 years for men 45–74 or women 40–74 with a parent, child or sibling who had lung cancer; or for 50–74 with 20 or more pack-years who still smoke and are willing to quit, or quit within 15 years (MOHW Dec 2024)
Japan40 and over, priority 40–69: chest X-ray with a questionnaire every year
Korea54–74 with 30 or more pack-years, still smoking or quit within 15 years: low-dose CT every 2 years

Stomach cancer

CountryProgramme
United StatesNo USPSTF recommendation. Endoscopy to be considered for defined high-risk groups (AGA 2025)
TaiwanNo endoscopy programme. One H. pylori stool antigen test in a lifetime at 45–74, from 2026 (MOHW Jan 2026)
Japan50 and over, priority 50–69: gastroscopy or barium X-ray every 2 years. For now the X-ray may cover people from 40 and be offered yearly
Korea40 and over: gastroscopy every 2 years, or a barium upper GI series selectively

Liver cancer

CountryProgramme
United StatesHepatitis C blood test once at 18–79. Hepatitis B test for higher-risk people, such as those born where 2% or more carry it (USPSTF 2020). Ultrasound with AFP every 6 months for cirrhosis and some hepatitis B carriers (AASLD 2023)
TaiwanHepatitis B and C blood test once, for people born in 1986 or earlier, up to 79 (MOHW Nov 2025). If positive: liver blood tests and abdominal ultrasound every 3–6 months advised (HPA, 2024)
JapanHepatitis B and C blood tests offered by municipalities from 40 (MHLW fiscal 2024 report). No liver cancer screen in the national list
KoreaHepatitis B test at 40 (NHIS). Hepatitis C antibody test at 56, from 2025 (KDCA). 40 and over with cirrhosis, hepatitis B or hepatitis C: ultrasound and AFP every 6 months

Oral, prostate and thyroid cancer

CountryProgramme
United StatesOral: evidence insufficient for adults without symptoms (USPSTF 2013, grade I). Prostate: 55–69, PSA is an individual decision (grade C); 70 and over, recommends against (grade D) (USPSTF 2018, update in progress). Thyroid: recommends against screening adults without symptoms (USPSTF 2017, grade D)
TaiwanOral: 30 and over who chew betel nut, now or in the past, or smoke, oral exam every 2 years; Indigenous chewers from 18. Prostate: not in the programme, and the HPA says evidence that PSA lowers deaths is insufficient (HPA 2025). Thyroid: not in the programme
JapanNone of the three is in the programme
KoreaNone of the three is in the programme

Screenings you book with us are self-paid; Taiwan's National Health Insurance does not cover short-term visitors.

Where do the four programmes agree, and where do the tests differ?

The programmes differ in the first test, the starting age and the interval. Taiwan, Japan and Korea start colorectal screening with a stool test. The American Cancer Society's May 2026 update kept the US start at 45 and recommends blood-based tests only for people who decline or do not complete the preferred tests. For cervical screening, Korea still uses the Pap test while the others add or prefer HPV testing.

Lung screening differs most, because each country chose a different group: heavy smokers in the US and Korea, people with a family history in Taiwan whether or not they smoked, and everyone from 40 with a chest X-ray in Japan.

The trials favour CT over X-ray for heavy smokers. In the US National Lung Screening Trial of 53,454 high-risk people, three yearly low-dose CT scans cut lung cancer deaths by 20.0% compared with chest X-ray. In the US PLCO trial, four yearly chest X-rays did not lower lung cancer deaths compared with usual care (rate ratio 0.99). This article does not assess the evidence behind Japan's guideline. Taiwan's main evidence for its family-history group is the TALENT study of 12,011 never-smokers and light smokers, which measured how many cancers screening found, not deaths. See our low-dose lung CT page.

Why do Japan and Korea screen the stomach, and Taiwan does not?

Stomach cancer is far more common in Japan and Korea than in Taiwan or the US (rates in the table below). Korea has measured its own programme. A nested case-control study inside it drew on 16,584,283 adults aged 40 and over. People who had ever had a screening gastroscopy had 47% lower odds of dying of stomach cancer than people never screened (odds ratio 0.53). The barium upper GI series showed no such link (odds ratio 0.98). It was not a randomised trial.

Taiwan's health ministry states that about 80 to 90% of stomach cancers are caused by H. pylori infection. Since 1 January 2026, Taiwan has offered people 45 to 74 one H. pylori stool antigen test in a lifetime. Our H. pylori article covers the Matsu Islands study of mass H. pylori eradication in Taiwan.

The US has no population programme for the stomach. The American Gastroenterological Association's 2025 update says defined high-risk groups should be considered for screening, names endoscopy as the best test and calls H. pylori eradication essential. Our gastroscopy and colonoscopy page explains the procedure.

Why do Taiwan and Korea single out the liver?

Liver cancer is common in both, and the Health Promotion Administration states that about 80% of Taiwan's liver cancer patients have chronic hepatitis B or C. All four countries start with a blood test for the viruses. After a positive result, Korea scans adults 40 and over with cirrhosis, hepatitis B or C every 6 months, by ultrasound with an AFP blood test. Taiwan advises liver blood tests and abdominal ultrasound every 3 to 6 months. The US has no national programme for the scan, but the American Association for the Study of Liver Diseases recommends ultrasound with AFP every 6 months for cirrhosis and for hepatitis B carriers with added risk, such as men over 40 or women over 50 from countries where the virus is common. Japan has no liver cancer screen in its national list.

The evidence for the 6-month scan comes from people who already carry hepatitis B. A Shanghai trial of 18,816 people aged 35 to 59 with hepatitis B infection or chronic hepatitis found that screening every 6 months with AFP and ultrasound cut liver cancer deaths by 37%. It excluded people without liver disease, so the useful order is a blood test first and a scanning schedule only if it is positive. Our abdominal ultrasound page explains what the scan can and cannot see.

Why does Taiwan screen the mouth?

Oral cancer is far more common in Taiwan than in the other three countries (see table below), and Taiwan has screened betel-nut chewers and smokers since 2004. A 2017 evaluation covered 2,334,299 smokers and betel quid chewers. Before any adjustment, screened people had a 47% lower risk of dying of oral cancer than expected (relative risk 0.53). After adjusting for self-selection (people who attend differ from those who do not), the reduction was 26% (relative risk 0.74).

This is an observational result in a high-risk group, and the USPSTF finds the evidence insufficient for adults without symptoms. If you neither chew betel nut nor smoke, Taiwan's own programme would not screen you.

Why does no Asian national programme screen for prostate or thyroid cancer?

Japan's National Cancer Center says the state does not recommend screening outside its list of five, because benefit in reducing cancer deaths has not been established for the others. Taiwan's Health Promotion Administration states there is not yet enough evidence that PSA testing lowers prostate cancer deaths, and warns of overdiagnosis and overtreatment.

For prostate cancer, our prostate exam page compares the guidance. For thyroid cancer, the USPSTF recommends against screening adults without symptoms. Recorded thyroid cancer rates for both sexes are 32.0 per 100,000 in Korea, 17.43 in Taiwan, 10.7 in the US and 8.8 in Japan. Our article on overdiagnosis explains what happened when Korean clinics offered thyroid ultrasound alongside the national programme.

Which cancers are more common in each country?

The table shows new cases among men per 100,000, age-standardised to a world population, as each source prints them.

Cancer, menUnited StatesTaiwanJapanKoreaWho screens for it
Stomach5.110.5148.233.9Japan and Korea; Taiwan tests for H. pylori
Liver8.331.1314.820.6Korea, in carriers and cirrhosis
Nasopharynx0.575.900.500.91None of the four
Lip and oral cavity6.527.554.72.4Taiwan, in chewers and smokers

Taiwan's figures, including its thyroid rate above, are its cancer registry's 2023 age-standardised rates as published. Taiwan is not listed separately in GLOBOCAN, so the other columns are GLOBOCAN 2024 estimates. Read the gaps, not the decimals.

Nasopharyngeal cancer shows that a high rate alone does not create a programme. Taiwanese men's rate is over six times that of the other three countries, and Taiwan recorded 1,456 new cases in 2023, yet none of the four lists screens for it. A Hong Kong study tested 20,174 people for Epstein-Barr virus (EBV) DNA in the blood. Of 34 cancers found after persistently positive results, 71% were at stage I or II, against 20% in an earlier group of patients. It did not compare deaths with an unscreened group.

Why does a private check-up include tests no national programme pays for?

A national programme spends public money across a whole population, so it asks for proof that a test reduces deaths. A private check-up sells what the buyer chooses. Japan's National Cancer Center states the programme rule plainly: screening should be certain to reduce cancer deaths, and its benefits should outweigh its harms. It names the tests private check-ups add, CT, PET and tumor markers, as useful for checking recurrence and spread but not recognised as cancer screening.

Programmes also screen by risk. Taiwan's oral exam requires betel-nut chewing or smoking, and Korea's liver scan requires hepatitis or cirrhosis. A check-up that offers the same test to everyone drops the risk filter that the programme's evidence depends on.

Which Asian extras should a US reader add, and which can they skip?

Start with what US guidelines recommend for your age and sex, then add an extra only if you belong to the risk group its evidence comes from.

ExtraEvidenceWho it fitsOurs, with our price
Upper endoscopy (gastroscopy)Korea: 47% lower odds of stomach cancer death after screening gastroscopy (case-control)The AGA 2025 groups: immigrants from high-incidence regions, a first-degree relative with stomach cancer, hereditary syndromesUpper Endoscopy & Colonoscopy at iHope Clinic, $499; Upper Endoscopy as an add-on, $250
H. pylori testTaiwan funds one test at 45–74The groups listed in our H. pylori articleH Pylori Breath Test at iHope Clinic, $75
Hepatitis B and C blood testUSPSTF grade B for bothHepatitis C: every adult 18–79, once. Hepatitis B: if born where 2% or more carry itIncluded in Vital ($699), Premium ($1,699) and Advanced ($3,499); Comprehensive Blood Work Panel add-on, $249
Liver ultrasound every 6 monthsShanghai trial in hepatitis B carriers: 37% fewer liver cancer deathsCirrhosis, or hepatitis B with added risk (AASLD). Not people without liver diseaseiHope Clinic Abdomen Ultrasound, $95
Low-dose lung CT for never-smokersTALENT found more cancers with a family history; deaths not measuredNever-smokers with a first-degree relative with lung cancer, accepting that the effect on deaths is unprovenLow-Dose Lung CT included in Light ($1,399), Premium ($1,699), Complete ($1,699), Plus ($3,099) and Advanced ($3,499)
Oral cancer examTaiwan: 26% lower risk of oral cancer death (observational). USPSTF: insufficientBetel-nut chewers and smokersNot sold as a separate screen
Tumor marker panelNot recognised as screening by Japan's National Cancer Center. The Hong Kong EBV DNA study measured detection, not deathsNobody, as a screen; see our tumor markers pageiHope Clinic Tumor Markers Panel, $245. It includes EBV VCA IgA, an antibody test, not the DNA test the Hong Kong study used
Thyroid ultrasoundUSPSTF grade D; in no programmeNobody without a lump or symptom; see our thyroid ultrasound pageIncluded in Light, Complete and Plus
PSAUSPSTF grade C at 55–69, D from 70Men 55–69 who have weighed benefits and harms with a doctorProstate Exam at iHope Clinic, $150

Prices are ours, in US dollars; package contents are on our health screening page. See what to add and what to skip and taking Taiwan results to your own doctor.

Sources